Laboratory diagnosis and molecular basis of mild von willebrand disease type 1

Acta Haematologica

Volumn 121, Issue 2-3, 2009, Pages 85-97

  Michiels, Jan Jacques ^a,c,d   Berneman, Zwi ^a   Gadisseur, Alain ^a   Van Der Planken, Marc ^a   Schroyens, Wilfried ^a   Van Vliet, Huub H D M ^b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Goodheart Institute   (Netherlands)

^d Hemostasis Thrombosis Science Center   (Netherlands)

Author keywords

Blood group O; C1584 mutation; Type Vicenza; Von Willebrand disease type 1; Von Willebrand factor multimer

Indexed keywords

DESMOPRESSIN; VON WILLEBRAND FACTOR; ARGIPRESSIN[1 DEAMINO]; DIAGNOSTIC AGENT; RISTOCETIN;

BLOOD GROUP ABO SYSTEM; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE FREQUENCY; HEMOPHILIA; HUMAN; LABORATORY DIAGNOSIS; MISSENSE MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; REVIEW; THROMBOCYTE AGGREGATION; VON WILLEBRAND DISEASE; VON WILLEBRAND DISEASE TYPE 1; BLEEDING TIME; CHEMICAL STRUCTURE; CHEMISTRY; CLASSIFICATION; DOMINANT GENE; DOSE RESPONSE; DRUG EFFECT; GENETICS; GENOTYPE; PROTEIN QUATERNARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; RECESSIVE GENE; STOP CODON;

ABO BLOOD-GROUP SYSTEM; BLEEDING TIME; CODON, NONSENSE; DEAMINO ARGININE VASOPRESSIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, DOMINANT; GENES, RECESSIVE; GENOTYPE; HUMANS; MODELS, MOLECULAR; MUTATION, MISSENSE; PLATELET AGGREGATION; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; RISTOCETIN; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 67649669939     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000214847     Document Type: Review

References (41)

1. Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet HHDM: Characterization of recessive severe type 1 and 3 von Willebrand disease (VWD), asymptomatic heterozygous carriers versus blood group O-related von Willebrand factor deficiency and dominant type 1 VWD. Clin Appl Thromb Hemost 2006; 12:277-295.
2. Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet HHDM: Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease. Clin Appl Thromb Hemost 2006; 12:397-420.
3. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, Federici AB, Working Party on von Willebrand Disease Classification: Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4:2103-2114.
4. Sadler JE: A revised classification of von Willebrand disease. For the Subcommittee of von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994; 71: 520-525.
5. Michiels JJ, van de Velde A, van Vliet HHDM, van der Planken M, Schroyens W, Berneman Z: Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Semin Thromb Hemost 2002;28:111- 131.
6. Fressinaud E, Veyradier A, Truchard F, Martin I, Boyer-Neumann C, Trosseart M, Meyer D: Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998;91:1325- 1331.
7. Fressinaud E, Veyradier A, Sigaud M, Boyer-Neumann C, Le Boterff C, Meyer D: Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyzer at high shear rates. Br J Haematol 1999;106:777-783.
8. Franchini M, Gandini G, Manzato F, Lippi G: Evaluation of the PFA-100 system for monitoring desmopressin therapy in patients with type 1 von Willebrand's disease. Haem atolog ic a 2002;87:670.
9. Van Vliet HHDM, Kappers-Klunne MC, Leebeek F, Michiels JJ: PFA-100 monitoring of von Willebrand factor (VWF) responses to DDAVP and FVIII/VWF concentrate in von Willebrand disease type 1 and 2. Thromb Haemost 2008:100:462-468.
10. Cejka J: Enzyme immunoassay for FVIII-related antigen. Clin Chem 1984;28:1356-1358.
11. Brown JE, Bosak JO: An ELISA test for the binding of von Willebrand factor antigen to collagen. Thromb Res 1986; 43:303-311.
12. Favaloro EJ, Kershaw G, Bukuya M, Hertzberg M, Koutts J: Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100® and vWF:CBA as combined diagnostic strategies. Haemophilia 2001;7:180-189.
13. Sadler FE: von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003; 101: 2089-2093.
14. Gill JC, Endress-Brooks J, Bauer PJ, Marks WJ, Montgomery JF: The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69:1691-1695.
15. University of Sheffield: ISTH SSC VWF Database. http://www.vwf.group. shef.ac.uk/index.html
16. Schneppenheim R, Krey S, Bergmann F, Bock D, Budde U, Lange M, Linde R, Mittler U, Meili E, Mertes G, Olek K, Plendl H, Simeoni E: Genetic heterogeneity of severe von Willebrand disease type III in the German population. Hum Genet 1994;94:640-652.
17. Zhang ZP, Blomback M, Egberg N, Falk G, Anvret M: Characterization of the von Willebrand factor gene in von Willebrand disease type III patients from 24 families of Swedish and Finnish origin. Genomics 1994; 21: 189-183.
18. Zhang A, Lindstedt M, Blomback M: Effects of the mutant von Willebrand factor gene in von Willebrand disease. Hum Genet 1995; 96:388-394.
19. Eikenboom JCJ, Castaman G, Vos HL, Bertina RM, Rodeghiero F: Characterization of the genetic defects in recessive type 1 and type 3 von Willebrand patients of Italian origin. Thromb Haemost 1998;79:709-717.
20. Baronciani L, Cozzi G, Canciani MT, Peyvandi F, Srivastava A, Federici AB, Mannucci PM: Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease. Thromb Haemost 2000; 84: 536-540.
21. Eikenboom JCJ: Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. Best Pract Res Clin Haematol 2001;14:365-379.
22. Castaman G, Eikenboom JCJ: ABO blood group also influences the von Willebrand factor (VWF) antigen level in heterozygous carriers of VWF null alleles, type 2N mutation Arg854Gln, and the missense mutation Cys2363Phe. Blood 2002; 100:1927-1928.
23. Gadisseur AP, Vrelust I, Vangenechten I, Schneppenheim R, van der Planken M: Identification of a novel candidate splice site mutation (0874+1G→A) in a type 3 von Willebrand disease patient. Thromb Haemost 2007;98:464-466.
24. Lethagen S, Isaksson C, Schaedel C, Holmberg L: von Willebrand's disease caused by compound heterozygosity for a substitution mutation (T1156M) in the D3 domain of the von Willebrand factor and a stop mutation (Q2470X). Thromb Haemost 2002;88:421- 426.
25. Gallinaro L, Cattini MG, Sztukowska M, Padrini R, Sartorello F, Pontara E, Bertomoro A, Daidone V, Pagnan A, Casonato A: A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008;111:3540-3545.
26. Castaman G, Rodeghiero F, Tosetto A, Cappelletti A, Baudo F, Eikenboom JC, Federici AB, Lethagen S, Linari S, Lusher J, Nishino M, Petrini P, Srivastava A, Ungerstedt JS: Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2006;4:2164-2169.
27. Gadisseur A, Berneman Z, Schroyens W, Michiels JJ: Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1- C2 domains of the von Willebrand factor gene: role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio. Acta Haematol 2009;121: 128-138.
28. Hermans C, Battle J: Autosomal dominant von Willebrand disease type 2M. Acta Haematol 2009;121:139-144.
29. Gadisseur A, van der Planken M, Schroyens W, Berneman Z, Michiels JJ: Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene. Acta Haematol 2009;121:145-153.
30. Goodeve A, Eikenboom JCJ, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi Soteh M, Baronciani L, Hallden C, Guilliatt A, Lester W, Peake I: Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand disease (MCMDM-1V WD). Blood 2007;109: 112-121.
31. James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, Tinlin S, Brown C, Andrews C, Labelle A, Chirinian Y, O'Brien L, Othman M, Rivard G, Rapson D, Hough C, Lillicrap D: The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007;109:145-154.
32. Cumming A, Grundy P, Keeney S, Lester W, Enayat S, Guilliatt A, Bowen D, Pasi J, Keeling D, Hill F, Bolton-Maggs PH, Hay C, Collins P, the UK Haemophilia Centre Doctors' Organisation: An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006;96:630- 641.
33. Collins PW, Cumming AM, Goodeve A, Lillicrap D: Type 1 von Willebrand disease: application of emerging data to clinical practice. Haemophilia 2008;14:685-696.
34. Michiels JJ, Gadisseur A, van der Planken M, Schroyens W, Berneman Z: Dominant VWD type 1/2E and Vicenza: a clearance defect due to mutation inside the D3 multimerization domain clearly differs from mild VWD type 1 secretion defects due to mutations in the D1, D2, D4 (except S2179F), B1-2, C1-2 domains of the VWF gene. Proceedings European Workshop on VWF/VWD. Antwerp, University Press, 2008.
35. Davies JA, Collins PW, Hathaway L, Bowen DJ: The effect of von Willebrand factor Y/ C1584 on in vivo protein level and function, and interaction with ABO blood group. Blood 2007;109:2840-2846.
36. Davies JA, Collins PW, Hathaway L, Bowen DJ: von Willebrand factor: evidence for variable clearance in vivo according to Y/C1584 phenotype and ABO blood group. J Thromb Haemost 2008;6:97-103.
37. O'Brien LA, James PD, Othman M, Berber E, Cameron C, Notley CR, Hegadorn CA, Sutherland JJ, Hough C, Rivard GE, O'Shaunessey D, Lillicrap D, Association of Hemophilia Clinic Directors of Canada: Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease. Blood 2003;102:549-557.
38. Budde U, Schneppenheim R: Multimeric pattern in patients diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD). 51th Annu Meet ISTH, Sydney, 2005, poster P2057.
39. Schneppenheim R, Marggraf O, Eckert K, et al: Molecular background of 'smeary' von Willebrand factor multimers. Annual Meeting American Society of Hematology (abstract 2711, poster 901-II). Blood 2007;110: 709a.
40. Budde U, Schneppenheim R, Eikenboom JCJ, Goodeve A, Will K, Drewke E, Castaman G, Rodeghiero F, Federici AB, Batlle J, Pérez A, Meyer D, Mazurier C, Goudemand J, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I: Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European Study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebra nd disease (MCMDM1V WD). J Thromb Haemost 2008;6:762- 771.
41. Haberichter SL, Balistreri M, Christopherson P, Morateck P, Gavazova S, Bellissimo DB, Manco-Johnson MJ, Gill JC, Montgomery RR: Assay of von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006; 108: 334 4 -3351.